Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis

OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte–macrophage colony‐stimulating factor receptor α. We undertook to determine the long‐term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open‐label extension...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Arthritis Rheumatol
Main Authors: Burmester, Gerd R., McInnes, Iain B., Kremer, Joel M., Miranda, Pedro, Vencovský, Jiří, Godwood, Alex, Albulescu, Marius, Michaels, M. Alex, Guo, Xiang, Close, David, Weinblatt, Michael
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Rheumatoid Arthritis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947536/
https://ncbi.nlm.nih.gov/pubmed/29361199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40420
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares